Oculis Holding AG (OCS) Operating Leases (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Operating Leases came in at $2.3 million in Q1 2026, up 163.25% year-on-year from $888688.2 in Q1 2025, and up 3.25% quarter-over-quarter from $2.3 million in Q4 2025.
Oculis Holding AG (OCS) Operating Leases (2021 - 2026) Analysis & Trends
Oculis Holding AG's Operating Leases history runs 6 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- On a quarterly basis, Operating Leases rose 163.25% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 163.25% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, up 122.15% from the prior year.
- Operating Leases rose to $2.3 million in Q1 2026 per OCS's latest filing, from $2.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $2.6 million in Q3 2025 and bottomed at $470875.4 in Q1 2024.
- The 5-year median for Operating Leases is $888688.2 (2025), against an average of $1.2 million.
- Across the five-year window, Operating Leases decreased 22.21% in 2025 and soared 163.25% in 2026, its largest moves.
- Year by year, Operating Leases stood at $657067.9 in 2022, then increased by 3.8% to $682049.5 in 2023, then surged by 44.77% to $987416.4 in 2024, then surged by 129.47% to $2.3 million in 2025, then advanced by 3.25% to $2.3 million in 2026.
- Per Business Quant, the three latest OCS Operating Leases figures stand at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 869,680.96 |
| Mar 31, 2025 | 888,688.18 |
| Dec 31, 2024 | 987,416.40 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 470,875.43 |
| Dec 31, 2023 | 682,049.46 |
| Sep 30, 2023 | 571,737.04 |
| Jun 30, 2023 | 599,462.62 |
| Dec 31, 2022 | 657,067.87 |
| Dec 31, 2021 | 625,757.71 |